
MOLECULAR SYNTHETICS LIMITED

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2019

MOLECULAR SYNTHETICS LIMITED
REGISTERED NUMBER: 04988521

BALANCE SHEET
AS AT 31 DECEMBER 2019

	Note	2019 £	2018 £
CURRENT ASSETS			
Debtors: amounts falling due within one year	4	100	100
Creditors: amounts falling due within one year	5	(95,399)	(93,659)
NET CURRENT LIABILITIES		(95,299)	(93,559)
NET LIABILITIES		(95,299)	(93,559)
CAPITAL AND RESERVES			
Called up share capital	6	1,000	1,000
Profit and loss account		(96,299)	(94,559)
		(95,299)	(93,559)

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

Dr M Bacon
Director

Date: 15 December 2020

The notes on pages 2 to 3 form part of these financial statements.

MOLECULAR SYNTHETICS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019**

1. GENERAL INFORMATION

Molecular Synthetics Limited is a private company limited by shares and incorporated in England and Wales. The address of the registered office is Salisbury House, Station Road, Cambridge, CB1 2LA. The company has no permanent trading premises.

The Company's functional and presentational currency is GBP and the figures are rounded to the nearest pound.

2. ACCOUNTING POLICIES

2.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

2.2 GOING CONCERN

In common with other development stage companies, the company has incurred a loss for the year and has net liabilities at the year end. The company has received assurances from the directors that they will continue to provide ongoing financial support to the company, and consequently the accounts are prepared on the going concern basis.

2.3 DEBTORS

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

CREDITORS

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

3. EMPLOYEES

The Company has no employees other than the directors, who did not receive any remuneration (2018 - £NIL).

4. DEBTORS

	2019 £	2018 £
Called up share capital not paid	100	100
	<u>100</u>	<u>100</u>

MOLECULAR SYNTHETICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2019	2018
	£	£
Trade creditors	4,313	3,143
Other creditors	89,886	89,346
Accruals and deferred income	1,200	1,170
	<u>95,399</u>	<u>93,659</u>

6. SHARE CAPITAL

	2019	2018
	£	£
ALLOTTED, CALLED UP AND FULLY PAID		
900 (2018 - 900) Ordinary shares of £1 each shares of £1.00 each	<u>900</u>	<u>900</u>
ALLOTTED, CALLED UP AND PARTLY PAID		
100 (2018 - 100) Ordinary shares of £1 each shares of £1.00 each	<u>100</u>	<u>100</u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.